3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
42
Breast Neoplasms
28
Parkinson Disease 4, Autosomal Dominant Lewy Body
23
Neoplasms
22
Multiple Myeloma
18
Leukemia, Myeloid, Acute
14
Neoplasm Metastasis
11
Carcinoma, Renal Cell
10
Leukemia
10
Melanoma
10
Ovarian Neoplasms
10
Recurrence
10
Leukemia, Lymphocytic, Chronic, B-Cell
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Adenocarcinoma
8
Carcinoma, Hepatocellular
8
Colorectal Neoplasms
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lung Neoplasms
8
Myelodysplastic Syndromes
8
Prostatic Neoplasms
8
Stomach Neoplasms
8
Lymphoma, Follicular
7
Bronchiolitis Obliterans Syndrome
6
Carcinoma
6
Lymphoma
6
Lymphoma, Non-Hodgkin
6
Small Cell Lung Carcinoma
6
Urinary Bladder Neoplasms
6
Cholangiocarcinoma
5
Interventions
loncastuximab tesirine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Has announcements
×
Diffuse Large B-Cell Lymphoma Refractory
×
Clear all
NCT03589469
2023-08-29
LOTIS-2
ADC Therapeutics S.A.
Phase 2
Completed
145 enrolled
24 charts
1 FDA